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AnalysisOnly 5 years ago, it was a multimillion-
dollar proposition. But today, the 3 billion 
base pairs of a human genome can be 
sequenced for about $50,000, and prices 
are expected to drop by more than half 
by year’s end. It’s still a hefty price tag, 
especially if you add to it the time and 
resources needed to interpret the data. 
But the drop in costs now makes it fea-
sible to sequence the entire genome of 
patients and their families to find elusive 
disease-causing mutations.
Researchers currently rely on microar-
rays containing common human single-
nucleotide polymorphisms (SNPs) to 
quickly scan the genomes of hundreds 
or thousands of individuals at once to 
pull out variations associated with dis-
ease. But despite an explosion of data 
from these so-called genome-wide 
association studies, the variations iden-
tified only account for a small propor-
tion of the genetic risk of developing a 
disease. Whole-genome sequencing 
promises to uncover this hidden genetic 
risk. By sequencing the entire genome 
of an individual and then comparing the 
sequence to that of a reference human 
genome, researchers can catalog every 
single variation in the DNA code of that 
particular individual. Bioinformatics tools 
can then home in on the variations asso-
ciated with a particular trait or condi-
tion. Once enough genome sequences 
have been amassed, whole-genome 
sequencing then could be used to diag-
nose disease or to inform the best thera-
peutic options.
As sequencing costs continue to plum-
met and bioinformatics tools mature, 
whole-genome sequencing is poised 
to replace other tools of the genomics 
trade. “It’s definitely the way forward,” 
says Richard Gibbs of the Baylor College 
of Medicine in Texas, whose group has 
just reported a pioneering study using 
whole-genome sequencing to identify 
mutations that cause the hereditary dis-
order Charcot-Marie-Tooth disease (N. 
Engl. J. Med., 2010, 362, 1181–1191).
Going after Mendelian Diseases
Since coming on the market in 2005, next-
generation sequencing methods have 
greatly increased sequencing speeds 
and have driven down costs, compared 
to the original Sanger sequencing method 
used by the Human Genome Project. The 
immediate application of whole-genome 
sequencing using next-generation tech-
nologies is to search for mutations respon-
sible for single-gene (Mendelian) diseases 
or monogenic traits. Gibbs sequenced 
the whole genome of his colleague James 
Lupski, a prominent medical geneticist 
who has Charcot-Marie-Tooth disease, a 
neurological disorder that causes muscle 
weakness. Mutations in over 30 different 
genes, many of them identified by Lupski 
himself, give rise to this condition, but Lup-
ski did not carry any of them.
Comparison of Lupski’s full genome 
sequence to the Human Genome Project 
reference sequence revealed many differ-
ences that greatly exceeded the number 
of known SNPs and other variations. As a 
result, Gibbs and Lupski had to determine 
which of these variations were disease-
associated mutations, harmless variations, 
or just errors in sequencing. “This is going 
to be a common problem for all sequenc-
ing projects,” says Gibbs. “We are going 
to find many more mutations than are cur-
rently in databases, so you need to find a 
way to narrow down the hits.”
So, the researchers focused on select 
variations found in genes previously 
linked to Charcot-Marie-Tooth disease 
and other nerve disorders. They found 
two compelling mutations, one in each 
allele, of a gene called SH3TC2, which 
is expressed in the Schwann cells that 
wrap the myelin sheath around nerves. 
Of Lupski’s seven siblings, the three with 
Charcot-Marie-Tooth disease carried 
both mutations and the four without the 
disease did not, confirming that the dis-
ease-causing mutations had been iden-
tified. “This is the first demonstration of 
using full blown sequencing in a clinically 
relevant approach,” says Gibbs.
Similarly, Leroy Hood and David Galas 
at the Institute for Systems Biology in 
Seattle analyzed the entire genomes of 
four members of one family in which two 
children had different single-gene reces-
sive diseases (Miller syndrome and pri-
mary ciliary dyskinesia; Science, 2010, 
328, 636–639). By comparing the four 
sequences, “we found that sequencing 
errors are about 1000 times more preva-
lent than true mutations,” says Galas. 
“Distinguishing errors from variations in 
the sequence is more difficult to do if you 
are just sequencing unrelated individu-
als and comparing them to a reference 
genome.”
Once they had eliminated sequenc-
ing errors and obtained a list of possible 
genetic variations in each individual, the 
group looked specifically for rare missense 
mutations (which would cause amino acid 
changes) in the coding sequences of 
genes located within chromosome seg-
ments inherited by both siblings. They 
reduced the number of possible variations 
responsible for the two conditions to four. 
“We used a simple model of rare SNPs in 
exons that cause missense mutations and 
found that applying that model eliminates 
all but four genes,” says Galas. “We were 
amazed at how well it worked.”
They also obtained the first direct esti-
mate of how much the genome changes 
from one generation to the next and 
found the mutation rate (1.1 × 10−8 muta-
tions per position per generation per 
haploid genome) to be about half the 
predicted number. Galas and colleagues 
are now gearing up to sequence 30 indi-
viduals over 4 generations to obtain a 
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more precise estimate. “Then we could 
ask things like, ‘What does the mutation 
rate depend on?’” says Galas.
Finding answers about basic biological 
processes, such as mutation rates or dis-
ease mechanisms, is another application 
of whole-genome sequencing. “Individ-
ual genome sequencing so far has been 
primarily descriptive. It has been used to 
look at the features and landscape of the 
genome,” says Stephen Kingsmore of the 
National Center for Genome Resources 
in Santa Fe. Kingsmore recently used 
whole-genome sequencing to examine 
why in monozygotic (identical) twins dis-
cordant for multiple sclerosis—an auto-
immune disease that destroys the myelin 
sheath protecting nerve cells—one twin 
has the disease and the other does not 
(Nature, 2010, 464, 1351–1356).
His group sequenced the complete 
genomes of a monozygotic twin pair dis-
cordant for multiple sclerosis to look for 
variations that might explain the differ-
ence in disease manifestation but did not 
find any. “We did not find any sequence 
differences between twins in any unique 
genome sequence,” says Kingsmore. 
“This was a pioneering study to show 
how sequencing can be used to exam-
ine hypotheses.” Kingsmore also used 
sequencing to analyze differences in 
epigenetic markers and in transcripts 
between the genomes of this twin pair and 
again did not find any telltale differences. 
“A new paradigm in genome analysis is 
to include the functional genome and epi-
genome in relevant tissues,” he says, “in 
addition to just sequencing the canonical, 
static genome.”
More Sequence for Your Buck
Whole-genome sequencing requires 
tremendous computational power—for 
example, one complete human genome 
at 30-fold coverage requires 90 Gb of 
computer space—and sophisticated 
analyses. “The paper we published 
makes it look fairly straight forward. But 
that work involved large teams of people 
with expertise in biology and bioinfor-
matics, and we spent a lot of time ana-
lyzing the data,” says Gibbs.
Another challenge is that most high-
speed, next-generation instruments 
sequence DNA in very short segments, or 
reads, of about 100 base pairs, according 
to Jeff Schloss of the National Genome 
Research Institute. “This is a huge prob-
lem for understanding the structure of the 
genome.” Short reads make it impossible 
to independently assemble a genome 
sequence from scratch. Thus, research-
ers need to overlay their sequence data 
on a reference genome. But the sequence 
data cannot be sorted into the two sets 
of parental chromosomes, or haplotypes. 
And short reads make it difficult to detect 
variations other than single base-pair 
changes or very small deletions and inser-
tions. “There are new technologies that 
promise longer reads and are probably 
not going to be much more costly,” says 
Schloss. “Many people will want to get 
their hands on them.” Pacific Biosciences 
and Life Technologies plan to market these 
so-called third-generation sequencing 
machines within the next year or so. These 
instruments provide single-molecule reso-
lution—in other words, sequence informa-
tion from a single DNA strand—and can 
sequence reads of a thousand bases or 
more. In addition, some third-generation 
sequencing instruments should allow 
detection of methylation changes and the 
ability to directly sequence RNA.
Another problem is that the reference 
genome is not optimal for comparisons 
that involve complex datasets. In addition, 
databases of genome variations, such as 
SNP databases, are not sufficiently well 
populated to enable researchers to find 
matches for the thousands of changes 
they find in their sequencing efforts. Also, 
algorithms for interpreting sequence data 
are still not sufficiently mature to handle 
data from large numbers of individuals 
with many different diseases.
Given these challenges and the cost of 
whole-genome sequencing, some labs 
have opted only to sequence the exons, or 
exome, of an individual. Exome sequenc-
ing (about 1% of the whole genome) costs 
$5000 and requires simpler analysis. “We 
are interested in monogenic disorders 
and most mutations are found in coding 
regions of genes,” says Michael Bamshad 
at the University of Washington School of 
Medicine in Seattle. “At the moment, we 
think exome sequencing is a better use of 
resources.” Bamshad and colleague Jay 
Shendure sequenced the exomes of four 
individuals from three families that had a 
child with Miller syndrome. They mapped 
the mutation to the gene DHODH (which 
encodes an enzyme involved in pyrimi-
dine biosynthesis) that was also identified 
by Hood and Galas (Nat. Genet., 2010, 42, 
30–35).
Bamshad predicts that soon there will be 
many more reports of disease mutations 
identified by exome sequencing. “We and 
others have found additional genes using 
this method that will be published soon,” 
he says. Of course, exome sequencing 
will miss mutations that are in noncoding 
regions of the genome or in coding regions 
that have not yet been annotated. “We will 
probably get 1 in 2 or 1 in 3 mutations. This 
is because a lot of mutations are too subtle 
or they are not in what is known to be a 
transcript,” says Kingsmore.
Nonetheless, Kingsmore’s group has 
taken advantage of exome sequencing to 
develop a sequence-based test to identify 
people who carry mutations in a panel of 
500 genes that predispose to several child-
hood diseases. “It will be used for carrier 
testing, much like was done for Tay Sachs 
and other genetic diseases,” he says. 
Launching at the end of the year, it will be 
one of the first gene sequencing-based 
tests to come on the market. “These types 
of panels will be a great way to usher in 
genomics-based medicine,” he says.
Tackling Complex Diseases
One of the most exciting applications of 
whole-genome sequencing is to deci-
pher the molecular basis of complex 
diseases such as diabetes, cardiovas-
cular disease, autism, and schizophre-
nia, which are thought to be caused by 
combinations of several mutations and 
environmental factors.
Genome-wide association studies 
have picked up many of the more com-
mon variants associated with particular 
diseases. “But these studies have told 
us that the vast majority of the genetic 
risk of most common diseases is not 
explained by common variants and that 
most disease-related common variants 
have very small effects on disease risk,” 
says Richard Lifton at Yale University in 
Connecticut. “These findings suggest an 
alternative model in which individually 
rare variants with relatively large effects 
will play a substantial role.”
His group has demonstrated that rare 
heterozygous mutations in genes that 
cause recessive forms of low blood pres-
sure fit this model. “Those alleles are 
found collectively in 2% of the popula-918 Cell 141, June 11, 2010 ©2010 Elsevier Inc.
tion, but each one reduced the risk of 
hypertension by about 60%,” says Lif-
ton. He thinks that the same principle will 
apply to more common types of disease. 
“Because these variants are rare in the 
population, you will need large cohorts to 
distinguish functional variants from those 
that have no consequence,” he says. 
“That will be a significant challenge.”
Matthew State, also at Yale, is apply-
ing exome sequencing to elucidate the 
mechanisms involved in autism and other 
neurodevelopmental disorders. “There is a 
lot of evidence that multiple rare mutations 
will account for a good deal of autism,” 
says State. “Already the rare variants that 
have been identified so far have changed 
the way people think about autism.” For 
example, some of the known variants are 
involved in the mechanism by which nerve 
impulses in a presynaptic neuron increase 
the probability that the post synaptic neu-
ron will fire an action potential.
Using a large DNA repository from 1700 
families (comprising an autistic child, the 
parents, and an unaffected sibling), State 
and colleagues have started sequenc-
ing exomes. “Initially, we are sequenc-
ing trios—two parents and a child—and 
then picking out rare missense and non-
sense mutations that arise de novo in 
the affected children,” he says. “There 
is already a good deal of evidence that 
new mutations are important in autism 
and this approach is a great way of win-
nowing down the tremendous amount of 
rare variations we see in the exome.”
Although State believes that rare vari-
ants will reveal a great deal about both the 
genetic predisposition for and the molec-
ular mechanisms underlying autism, he is 
cautiously optimistic. “I also think there is 
a good chance that the genetic risks have 
been overestimated,” he says. “We will 
probably have to take into account other 
mechanisms such as epigenetics and 
environmental contributions.”
One of the biggest efforts to look for 
variants associated with complex traits is 
the Exome Sequencing Project funded by 
the National Heart, Lung and Blood Insti-
tute of the National Institutes of Health. 
The project aims to sequence about 8000 
exomes of individuals with common car-
diovascular and lung diseases like early 
myocardial infarction, stroke, and chronic 
obstructive pulmonary disease.
Whether rare alleles will individually 
account for a large proportion of genetic 
risk is debatable. “My expectation is that 
we will find many rare variants associ-
ated with common diseases but indi-
vidually they will not account for a large 
proportion of cases of disease,” says 
Kari Stefansson, president of the Icelan-
dic company DeCode Genomics. “The 
epidemiological data does not support 
this conclusion.” Instead, Stefansson 
predicts that common diseases will be 
caused by the “rare confluence of vari-
ants rather than just individual rare vari-
ants giving large effects,” he explains.
DeCode plans to sequence the entire 
genomes of 2000–2500 Icelanders, a 
population for which the company has 
already gathered extensive genotypic 
and medical data. This sequencing proj-
ect and other population-based studies 
such as the 1000 Genomes Project—
an international collaboration between 
China, Germany, the UK, and the US to 
sequence the whole genomes of about 
2000 individuals—will help to answer 
questions about the prevalence and 
role of rare variants in disease. “Once 
we have the sequence data, we won’t 
have to postulate any more and I pre-
dict we will all be very surprised,” says 
Stefansson.
Scrutinizing Cancer Genomes
Other whole-genome sequencing proj-
ects are looking at the sequences of dif-
ferent cancers. “In cancer, it is clear that 
each cancer cell will have thousands to 
tens of thousands of mutations. Most of 
them will be random, what we call pas-
senger mutations,” says Peter Campbell 
at the UK’s Sanger Institute. “But some, 
and we don’t know the number, will be 
driver mutations responsible for can-
cer development.” Campbell’s group is 
part of the International Cancer Genome 
Consortium, which plans to describe all 
genetic, transcriptional, and epigenetic 
changes in 50 different tumor types in 
25,000 cancer samples.
“What whole-genome sequencing is 
providing is discovery of all mutations 
without bias. We were sequencing genes 
before, but based on candidate genes 
we already knew were probably involved 
in cancer. So the sequencing merely 
allowed us to delve deeper into the 
mutations,” says John McPherson, at the 
Ontario Institute for Cancer Research in 
Toronto, whose group is sequencing the 
pancreatic cancer genome. “With unbi-
ased sequencing we can find anything. 
We will find new genes. This will help 
in the basic understanding of cancer 
mechanisms but also will help us define 
new subtypes.”
The picture emerging from cancer 
genomics is that specific cellular pathways 
are important in cancer development. 
“Driver mutations occur in certain genes at 
a higher frequency than they would only by 
chance, but they are still rare in the patient 
population. That is because one patient will 
have a mutation in one gene and another 
patient with the same type of cancer will 
have a different mutation in another gene, 
but the two genes are part of the same 
pathway,” says Campbell. “Each mutation 
is only found in a few percent of patients. 
But the pathway accounts for a large pro-
portion of patients.”
There are still many challenges before 
whole-genome sequencing goes main-
stream, but most geneticists agree that 
these are exciting times. “Five years ago, 
it was not clear what path these next-gen-
eration sequencing technologies would 
take because they had not been tested,” 
says Lifton. “It is quite astounding to be 
at this point now, where we can routinely 
get whole genome sequences of patients.” 
And as sequencing costs continue to 
plummet, more and more labs are getting 
into the sequencing game. “Large projects 
are still the domain of genome centers, 
but we are seeing more groups starting to 
sequence and providing valuable informa-
tion,” says Gibbs. “We are seeing a healthy 
proliferation of sequencing projects.”
Laura Bonetta
Washington DC
DOI 10.1016/j.cell.2010.05.034Cell 141, June 11, 2010 ©2010 Elsevier Inc. 919
